Vascular Biogenics Ltd. (NASDAQ: VBLT) stock jumped 12.30% on Friday to $0.16 against a previous-day closing price of $0.14. With 2.16 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.27 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.1610 whereas the lowest price it dropped to was $0.1452. The 52-week range on VBLT shows that it touched its highest point at $2.20 and its lowest point at $0.10 during that stretch. It currently has a 1-year price target of $5.00. Beta for the stock currently stands at 0.75.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VBLT was up-trending over the past week, with a rise of 10.19%, but this was up by 38.05% over a month. Three-month performance surged to 17.27% while six-month performance fell -57.75%. The stock lost -89.55% in the past year, while it has gained 32.42% so far this year. A look at the trailing 12-month EPS for VBLT yields -0.50 with Next year EPS estimates of -0.60. For the next quarter, that number is -0.14. This implies an EPS growth rate of 18.70% for this year and -15.40% for next year.
Float and Shares Shorts:
At present, 77.63 million VBLT shares are outstanding with a float of 53.36 million shares on hand for trading. On Oct 13, 2022, short shares totaled 0.16 million, which was 0.23% higher than short shares on Sep 14, 2022. In addition to Prof. Dror Harats M.D. as the firm’s CEO & Director, Dr. Eyal Breitbart Ph.D. serves as its Sr. VP of Research & Operations.
Through their ownership of 20.54% of VBLT’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 8.79% of VBLT, in contrast to 4.79% held by mutual funds. Shares owned by individuals account for 0.08%. As the largest shareholder in VBLT with 0.83% of the stake, Acadian Asset Management LLC holds 572,211 shares worth 572,211. A second-largest stockholder of VBLT, Two Sigma Investments LP, holds 425,993 shares, controlling over 0.61% of the firm’s shares. Telemetry Investments LLC is the third largest shareholder in VBLT, holding 400,000 shares or 0.58% stake. With a 0.06% stake in VBLT, the Fidelity Nasdaq Composite Index F is the largest stakeholder. A total of 40,323 shares are owned by the mutual fund manager. The Gestion Boutique IV FI – Gesem W-, which owns about 0.02% of VBLT stock, is the second-largest Mutual Fund holder. It holds 11,016 shares valued at 1322.0. Dolphin holds 0.01% of the stake in VBLT, owning 3,651 shares worth 438.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VBLT since 1 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With VBLT analysts setting a high price target of $5.00 and a low target of $5.00, the average target price over the next 12 months is $5.00. Based on these targets, VBLT could surge 3025.0% to reach the target high and rise by 3025.0% to reach the target low. Reaching the average price target will result in a growth of 3025.0% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. VBLT will report FY 2022 earnings on 03/20/2024. Analysts have provided yearly estimates in a range of -$0.52 being high and -$0.52 being low. For VBLT, this leads to a yearly average estimate of -$0.52. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Vascular Biogenics Ltd. surprised analysts by -$0.01 when it reported -$0.12 EPS against a consensus estimate of -$0.11. The surprise factor in the prior quarter was -$0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.14 and the low estimate is -$0.14. The average estimate for the next quarter is thus -$0.14.